EssilorLuxottica launch first U.S. joint product after merger

Article

RayBan Authentic offers new lens technology and customization

Photo by EssilorLuxottica

EssilorLuxottica, the combined company after the two entities announced a deal in 2017 and merged in 2018, have launched its first joint product.

Essilor and Luxottica have teamed up to bring a new generation of clear, gradient, and sun Ray Ban lenses to the U.S. market. The launch, Ray Ban Authentic, couples the iconic frames with the latest optical technologies from Essilor, according to the company.

EssilorLuxotica says it will offer premium and lightweight lenses that adapt to the shape and curvature of the Ray-Ban frame.

More on EssilorLuxottica

This collection includes 1,400 lens-frame combinations and will launch on January 19, 2021, according to the company. Consumers can expect the new range to include Transitions technology, photochromic lenses, and blue light filters along with innovative lens solutions.

"Private practices will now have an elevated and differentiated complete pair offering,” says Rick Gadd, president of Essilor North America, in a statement.

He says independent practitioners will see success by providing patients with style and sight with the new launch.

According to the EssilorLuxotica website, a virtual try-on tool will be available for consumers to choose their look in just a few steps at home. Additionally, a tool called Ray-Ban Remix allows patients to customize their experience.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.